Drug Nanocrystals: A Delivery Channel for Antiviral Therapies
Viral infections represent a significant threat to global health due to their highly communicable and potentially lethal nature. Conventional antiviral interventions encounter challenges such as drug resistance, tolerability issues, specificity concerns, high costs, side effects, and the constant mutation of viral proteins. Consequently, the exploration of alternative approaches is imperative. Therefore, nanotechnology-embedded drugs excelled as a novel approach purporting severe life-threatening viral disease. Integrating nanomaterials and nanoparticles enables ensuring precise drug targeting, improved drug delivery, and fostered pharmacokinetic properties. Notably, nanocrystals (NCs) stand out as one of the most promising nanoformulations, offering remarkable characteristics in terms of physicochemical properties (higher drug loading, improved solubility, and drug retention), pharmacokinetics (enhanced bioavailability, dose reduction), and optical properties (light absorptivity, photoluminescence). These attributes make NCs effective in diagnosing and ameliorating viral infections. This review comprises the prevalence, pathophysiology, and resistance of viral infections along with emphasizing on failure of current antivirals in the management of the diseases. Moreover, the review also highlights the role of NCs in various viral infections in mitigating, diagnosing, and other NC-based strategies combating viral infections. In vitro, in vivo, and clinical studies evident for the effectiveness of NCs against viral pathogens are also discussed. Graphical Abstract.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
---|---|
Enthalten in: |
AAPS PharmSciTech - 25(2024), 3 vom: 17. Feb. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Chaturvedi, Akanksha [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
BKL: | |
---|---|
Themen: |
Anmerkungen: |
© The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
---|
doi: |
10.1208/s12249-024-02754-5 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR05480020X |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR05480020X | ||
003 | DE-627 | ||
005 | 20240327064924.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240217s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1208/s12249-024-02754-5 |2 doi | |
035 | |a (DE-627)SPR05480020X | ||
035 | |a (SPR)s12249-024-02754-5-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a PHARM |q DE-84 |2 fid | ||
084 | |a 44.40 |2 bkl | ||
100 | 1 | |a Chaturvedi, Akanksha |e verfasserin |4 aut | |
245 | 1 | 0 | |a Drug Nanocrystals: A Delivery Channel for Antiviral Therapies |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
520 | |a Viral infections represent a significant threat to global health due to their highly communicable and potentially lethal nature. Conventional antiviral interventions encounter challenges such as drug resistance, tolerability issues, specificity concerns, high costs, side effects, and the constant mutation of viral proteins. Consequently, the exploration of alternative approaches is imperative. Therefore, nanotechnology-embedded drugs excelled as a novel approach purporting severe life-threatening viral disease. Integrating nanomaterials and nanoparticles enables ensuring precise drug targeting, improved drug delivery, and fostered pharmacokinetic properties. Notably, nanocrystals (NCs) stand out as one of the most promising nanoformulations, offering remarkable characteristics in terms of physicochemical properties (higher drug loading, improved solubility, and drug retention), pharmacokinetics (enhanced bioavailability, dose reduction), and optical properties (light absorptivity, photoluminescence). These attributes make NCs effective in diagnosing and ameliorating viral infections. This review comprises the prevalence, pathophysiology, and resistance of viral infections along with emphasizing on failure of current antivirals in the management of the diseases. Moreover, the review also highlights the role of NCs in various viral infections in mitigating, diagnosing, and other NC-based strategies combating viral infections. In vitro, in vivo, and clinical studies evident for the effectiveness of NCs against viral pathogens are also discussed. Graphical Abstract | ||
650 | 4 | |a antiretroviral |7 (dpeaa)DE-He213 | |
650 | 4 | |a antiviral |7 (dpeaa)DE-He213 | |
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a hepatitis B |7 (dpeaa)DE-He213 | |
650 | 4 | |a nanocrystal |7 (dpeaa)DE-He213 | |
700 | 1 | |a Sharma, Swapnil |4 aut | |
700 | 1 | |a Shukla, Rahul |0 (orcid)0000-0002-4864-0133 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t AAPS PharmSciTech |d Springer International Publishing, 2000 |g 25(2024), 3 vom: 17. Feb. |w (DE-627)SPR02478785X |w (DE-600)2052070-0 |x 1530-9932 |7 nnns |
773 | 1 | 8 | |g volume:25 |g year:2024 |g number:3 |g day:17 |g month:02 |
856 | 4 | 0 | |u https://dx.doi.org/10.1208/s12249-024-02754-5 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_SPRINGER | ||
912 | |a FID-PHARM | ||
912 | |a SSG-OLC-PHA | ||
912 | |a SSG-OPC-PHA | ||
936 | b | k | |a 44.40 |q VZ |
951 | |a AR | ||
952 | |d 25 |j 2024 |e 3 |b 17 |c 02 |